AB Science S.A (AB) - Total Liabilities
Based on the latest financial reports, AB Science S.A (AB) has total liabilities worth €48.54 Million EUR (≈ $56.75 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
AB Science S.A - Total Liabilities Trend (2009–2024)
This chart illustrates how AB Science S.A's total liabilities have evolved over time, based on quarterly financial data. Explore AB Science S.A long-term investment intensity to see how much of total assets are deployed in long-term investments.
AB Science S.A Competitors by Total Liabilities
The table below lists competitors of AB Science S.A ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
MCE Holdings Bhd
KLSE:7004
|
Malaysia | RM71.16 Million |
|
Mgame Corp
KQ:058630
|
Korea | ₩18.30 Billion |
|
SERESCO (ACC.P.DESD.)-16
F:XV7
|
Germany | €25.40 Million |
|
Permianville Royalty Trust
NYSE:PVL
|
USA | $0.00 |
|
Multifiling Mitra Indonesia
JK:MFMI
|
Indonesia | Rp328.16 Billion |
|
Fiducial Office Solutions
PA:SACI
|
France | €48.70 Million |
|
LapWall Oyj
HE:LAPWALL
|
Finland | €22.61 Million |
|
Electra Battery Materials Corp
V:ELBM
|
Canada | CA$100.05 Million |
Liability Composition Analysis (2009–2024)
This chart breaks down AB Science S.A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see AB total asset value.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.67 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.00 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.78 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 2.29 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how AB Science S.A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for AB Science S.A (2009–2024)
The table below shows the annual total liabilities of AB Science S.A from 2009 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €46.93 Million ≈ $54.86 Million |
+0.90% |
| 2023-12-31 | €46.51 Million ≈ $54.37 Million |
-21.85% |
| 2022-12-31 | €59.51 Million ≈ $69.57 Million |
+33.83% |
| 2021-12-31 | €44.47 Million ≈ $51.99 Million |
-9.68% |
| 2020-12-31 | €49.24 Million ≈ $57.56 Million |
+10.47% |
| 2019-12-31 | €44.57 Million ≈ $52.11 Million |
+19.00% |
| 2018-12-31 | €37.45 Million ≈ $43.79 Million |
-6.05% |
| 2017-12-31 | €39.87 Million ≈ $46.61 Million |
-6.67% |
| 2016-12-31 | €42.72 Million ≈ $49.94 Million |
-14.29% |
| 2015-12-31 | €49.84 Million ≈ $58.26 Million |
+6.13% |
| 2014-12-31 | €46.96 Million ≈ $54.90 Million |
+8.47% |
| 2013-12-31 | €43.29 Million ≈ $50.61 Million |
+72.59% |
| 2012-12-31 | €25.08 Million ≈ $29.32 Million |
+15.42% |
| 2011-12-31 | €21.73 Million ≈ $25.41 Million |
+48.69% |
| 2010-12-31 | €14.62 Million ≈ $17.09 Million |
+12.04% |
| 2009-12-31 | €13.04 Million ≈ $15.25 Million |
-- |
About AB Science S.A
AB Science S.A., a clinical-stage company, engages in the research, design, development, and marketing of drugs to address pathologies affecting the peripheral and central nervous system, inflammatory diseases, and cancers in France. The company's lead drug candidate is masitinib, a selective protein kinase inhibitor that targets mast cells and microglia in Phase 3 trial for the treatment of amyo… Read more